CAS: 37296-80-3; Colestipol Hydrochloride

该化合物是一种合成聚合化合物,主要用作治疗超脂性贫血的胆固醇低温剂,其作用是作为胆碱酯酶固凝剂,肠胃中捆绑的胆碱酸,防止其再吸附,导致胆固醇的排泄增加.这一机制促使肝脏使用更多的胆固醇合成新的胆碱酸,从而降低血液中胆固醇的总体水平.Colestipol 盐酸通常以平板或颗粒的形式施用,以相对较低的系统吸收为名,以其较低的系统吸收度为名,从而尽量减少潜在副作用.该物质的特点为白色与非白色的外表征,在水中溶解,适于口服.常见的副作用包括胃肠紊乱,如调调,泡泡,腹膜分泌等.与任何药物一样,病人必须咨询保健专业人员,以便适当施用,并讨论与其他药物的相互作用.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-2005255071-A1
    优先权日:1998-12-10
    标 题 :Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
    发明人:LINDNER JURGEN; HAASE BURKHARD
    权利人:AVENTIS PHARMA GMBH
    摘要:A preparation comprising a compound which essentially prevents the enterohepatic circulation of nucleotide synthesis inhibitors or antagonizes the action of the nucleotide synthesis inhibitors with a displacement in time, and a nucleotide synthesis inhibitor such as brequinar, mycophenolatemofetil (2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoate), methotrexate, mizoribine and compounds of formulae (I) and (II) n nis suitable for the treatment of immunological disorders, cancer, or in transplantations.

    专利号:US-8007994-B2
    优先权日:1998-12-10
    标题:Compositions and methods of modulating cholesterol metabolism
    发明人:MANGELSDORF DAVID J; REPA JOYCE J; TURLEY STEPHEN D; DIETSCHY JOHN M
    权利人:UNIV TEXAS
    摘要:The present invention relates to compositions and methods for reducing cholesterolemia and its effects. More specifically, the invention is directed, in one embodiment, to methods for screening for compounds that affect cholesterol levels generally, and in particular, that affect the absorption of cholesterol. The invention also is directed to methods of screening for compounds that increase bile acid synthesis. In so doing, the inventors describe useful transgenic cells and animals which lack one or both alleles of the LXRα gene. Also provided are therapeutic methods designed to reduce cholesterol levels in suitable subjects. The reduction may be effected by decreasing cholesterol absorption, increasing bile acid synthesis, or combinations thereof. Particularly useful in decreasing cholesterol absorption are RXR agonists, for example, rexinoid compounds. Therapeutic intervention in cholesterol biosynthesis and diet are additional adjunct therapies. In addition, the present invention relates to candidate compounds that modulate the expression of ABC-1 in a cell that expresses RXR. Methods of identifying and making a modulator of ABC-1 are disclosed.

    专利号:AU-2007308022-A2
    优先权日:2006-10-05
    标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:AU-2007308022-A1
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:US-2008107598-A1
    优先权日:2006-10-05
    标 题:Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications
    昆山化工医药原料有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.kshgyy.com
    电话: 86-0512-57665628👤
    📞昆山化工医药原料有限公司 ⚠️参考联系方式

    销售电话:86-0512-57665628
    邮箱:sale@kschempharm.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Colestipol. 2022 Sep 19. 2012–. Colestipol. 2017 Sep 28. 2023 Jan–. 115(10):1596-1603. doi: 10.14309/ajg.0000000000000696.
    5: Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet. 1997 Sep;33(3):184-213. doi: 10.2165/00003088-199733030-00003. 27(7-8):980-1. doi: 10.1177/106002809302700734. 21(4):513-6. doi: 10.1592/phco.21.5.513.34501. 64(1659):145-152. 61(1565):17-24. 27(11):653-9. doi: 10.1155/2013/485631.
    11: Franco J. Pruritus. Curr Treat Options Gastroenterol. 1999 Dec;2(6):451-456. doi: 10.1007/s11938-999-0048-8. 19(3):161-80. doi: 10.2165/00003495-198019030-00001. 2012–. Antilipemic Agents. 2019 Jun 4. 66(2):537-50. doi: 10.1016/s0025-7125(16)31434-1. 59(10):932-9. doi: 10.1093/ajhp/59.10.932. 30(2):99-106. doi: 10.1002/j.1552-4604.1990.tb03447.x. 30(6):985-92. doi: 10.1093/ajcn/30.6.985. 10(12):1403-1407. doi: 10.1080/17512433.2017.1395280. Epub 2017 Nov 2.

    合成参考文献


    参考文献:10.1007/s11894-011-0213-9
    摘要:Lichtenstein DR. Hepatobiliary complications of inflammatory bowel disease. Curr Gastroenterol Rep. 2011 Oct;13(5):495–505. doi: 10.1007/s11894-011-0213-9.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知